CancerDrs

Breast Cancer clinical trials in Virginia

49 actively recruiting breast cancer trials at 20 sites across Virginia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…

Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Virginia:
  • Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
  • VCU Massey Cancer Center at Hanover Medical Park — Mechanicsville, Virginia
  • Bon Secours Saint Francis Medical Center — Midlothian, Virginia
  • Naval Medical Center - Portsmouth — Portsmouth, Virginia
  • Bon Secours Saint Mary's Hospital — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Virginia:
  • Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
  • Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
  • Bon Secours Westchester Emergency Center — Midlothian, Virginia
  • Bon Secours Saint Francis Medical Center — Midlothian, Virginia
  • Bon Secours Richmond Community Hospital — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in Virginia:
  • Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia
  • Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
  • Bon Secours Saint Francis Medical Center — Midlothian, Virginia
  • Bon Secours Saint Mary's Hospital — Richmond, Virginia
  • Virginia Cancer Institute — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Virginia:
  • Inova Alexandria Hospital — Alexandria, Virginia
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Inova Fair Oaks Hospital — Fairfax, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Inova Loudoun Hospital — Leesburg, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…

Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Virginia:
  • Research Site — Charlottesville, Virginia
  • Research Site — Fairfax, Virginia
  • Research Site — Midlothian, Virginia
  • Research Site — Norfolk, Virginia
  • Research Site — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Virginia:
  • Mary Washington Hospital ( Site 0129) — Fredericksburg, Virginia
  • Hematology Oncology Associates of Fredericksburg ( Site 9550) — Fredericksburg, Virginia
  • Bon Secours Memorial Regional Medical Center-Oncology Research Department ( Site 0020) — Midlothian, Virginia
  • Virginia Oncology Associates (VOA) ( Site 8008) — Norfolk, Virginia
  • Virginia Cancer Institute ( Site 0034) — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Virginia:
  • Inova Alexandria Hospital — Alexandria, Virginia
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Inova Fair Oaks Hospital — Fairfax, Virginia
  • Inova Loudoun Hospital — Leesburg, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Virginia:
  • Inova Schar Cancer Institute ( Site 0025) — Fairfax, Virginia
  • Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015) — Midlothian, Virginia
  • VCU Health Adult Outpatient Pavillion ( Site 0070) — Richmond, Virginia
  • Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8001) — Roanoke, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in Virginia:
  • Virginia Oncology Associates (VOA) ( Site 8001) — Norfolk, Virginia
  • Shenandoah Oncology ( Site 8004) — Winchester, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…

Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in Virginia:
  • Virginia Cancer Institute — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Virginia:
  • Ballad Health Cancer Care - Bristol — Bristol, Virginia
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Henrico Doctor's Hospital — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Virginia:
  • Inova Health System — Falls Church, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …

Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Virginia:
  • Virginia Cancer Institute — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in Virginia:
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in Virginia:
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Virginia:
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Virginia Cancer Specialists, PC — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Virginia:
  • University of Virginia Health System — Charlottesville, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination…

Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05315700
Sites in Virginia:
  • Next Oncology — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Virginia:
  • Next Oncology Virginia — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Virginia:
  • NEXT Oncology — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of AVZO-021 in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 i…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT05867251
Sites in Virginia:
  • NEXT Virginia — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…

Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Virginia:
  • Virginia Cancer Institute — Norfolk, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06797635
Sites in Virginia:
  • Virginia Oncology Associates (VOA) ( Site 8001) — Norfolk, Virginia
View on ClinicalTrials.gov →

Showing 25 of 49 trials with sites in Virginia. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10